Unreasonable Collective Implementation of bio-equivalent Test

Published: 2001-08-14 06:56:00

Updated: 2001-08-14 06:56:00

The pharmaceutical industry issued a strong opinion that enforcing the bio-equivalent test only for the sake of substitutable dispensation without any consideration of economic factors should be stopped.

The KFDA has been receiving the requisition for the bio-equivalent test and as of August...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK